Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation
Hematol., Transfus. Cell Ther. (Impr.)
;
43(3): 332-340, July-Sept. 2021. tab, graf
Article
in English
| LILACS
| ID: biblio-1346264
ABSTRACT
Abstract Introduction:
The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures.Method:
Our goal is to propose a monoclonal antibody (MoAb) panel for MRD detection in ALL and provide recommendations intended for flow cytometry laboratories that work on 4-color flow cytometry platforms. Results andconclusion:
The document includes pre-analytical and analytical procedures, quality control assurance, technical procedures, as well as the information that needs to be included in the reports for clinicians.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Neoplasm, Residual
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Flow Cytometry
Type of study:
Practice guideline
/
Prognostic study
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Hematol., Transfus. Cell Ther. (Impr.)
Journal subject:
Hematologia
/
TransfusÆo de Sangue
Year:
2021
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital Amaral Carvalho/BR
/
Hospital Erasto Gaertner/BR
/
Sabin Medicina Diagnóstica/BR
/
Universidade Federal de São Paulo - UNIFESP/BR
/
Universidade Federal do Paraná - UFPR/BR
/
Universidade Federal do Rio de Janeiro - UFRJ/BR
Similar
MEDLINE
...
LILACS
LIS